Onconetix (NASDAQ:ONCO) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Onconetix (NASDAQ:ONCO) to a hold rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings cut Onconetix from a “sell (e+)” rating to a “sell (e)” rating in a research note on Friday, April 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Onconetix Price Performance

NASDAQ ONCO opened at $0.64 on Friday. The business has a 50 day simple moving average of $2.04 and a 200 day simple moving average of $7.72. Onconetix has a one year low of $0.57 and a one year high of $74.29. The stock has a market capitalization of $419,100.00, a P/E ratio of 0.00 and a beta of 3.01.

Insider Buying and Selling

In other Onconetix news, major shareholder Financial Lp Hrt sold 49,710 shares of the firm’s stock in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $0.69, for a total value of $34,299.90. Following the completion of the sale, the insider owned 33,649 shares of the company’s stock, valued at approximately $23,217.81. This trade represents a 59.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders purchased 201,540 shares of company stock valued at $152,875 and sold 198,039 shares valued at $144,469. Company insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Onconetix

An institutional investor recently bought a new position in Onconetix stock. Citadel Advisors LLC acquired a new stake in Onconetix, Inc. (NASDAQ:ONCO) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 15,633 shares of the company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned 1.00% of Onconetix as of its most recent filing with the Securities & Exchange Commission. 23.89% of the stock is owned by institutional investors.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.